AI in Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Component (Software Solutions, Hardware, Services), By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others), By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others), By Region, By Competition 2018-2028

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

 

Forecast Period

2024-2028

Market Size (2022)

USD 701.08 Million

CAGR (2023-2028)

14.02%

Fastest Growing Segment

Chemotherapy

Largest Market

North America
  

Market Overview

Global AI in Oncology Market has valued at USD 701.08 Million in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 14.02% through 2028. Artificial intelligence (AI) in oncology helps provide faster and more precise diagnoses of cancer, leading to improved patient outcomes – which is expected to fuel the market during the forecast period. The growth in healthcare infrastructure and an increasing prevalence of cancer is expected to drive maret expansion during the forecast period. One factor driving market expansion during the pandemic was the increased adoption of AI to diagnose, treat, and analyze complex datasets, this reduced burdens on hospitals and physicians alike.

Key Market Drivers

Improving Diagnostic Accuracy

AI algorithms excel in analyzing medical images, such as X-rays, MRIs, and CT scans, with high precision. By accurately identifying potential tumors and assessing their characteristics, AI aids in early cancer detection. Early detection is critical for effective treatment and improved survival rates. Consequently, healthcare providers and patients alike are increasingly relying on AI-based diagnostic tools to detect cancer at its earliest, most treatable stages. Human errors and variability in interpreting medical images can lead to misdiagnoses. AI systems offer consistency and objectivity in analysis, significantly reducing the chances of misdiagnosis. This, in turn, instills greater confidence in healthcare professionals and patients regarding the accuracy of cancer diagnoses, further driving the adoption of AI in oncology. Governments and healthcare organizations worldwide are investing in cancer screening programs. AI can help optimize these programs by automating the analysis of screening tests, such as mammograms and Pap smears.

The improved accuracy of these screenings can lead to early cancer detection, thereby increasing the demand for AI-driven solutions. Accurate diagnosis is the foundation for developing personalized treatment plans. AI not only helps in diagnosing cancer but also in characterizing tumors at a molecular level. This allows oncologists to tailor treatment strategies based on the specific genetic makeup and characteristics of the cancer, leading to more effective and targeted therapies. Patients are increasingly seeking personalized treatment options, driving the demand for AI in oncology. Timely and accurate diagnosis reduces the need for extensive, often costly, treatments and interventions at later stages of cancer. This can lead to substantial cost savings in the healthcare system, making AI-driven diagnostics an attractive option for healthcare providers and payers. AI systems can analyze medical images much faster than humans and are available 24/7. This efficiency can streamline clinical workflows, allowing healthcare providers to see more patients and manage their resources more effectively. This increased efficiency is a compelling factor for healthcare institutions looking to optimize their operations.

Growing Personalized Treatment Plans

AI-driven analysis of patient data, including genetic information and tumor characteristics, enables the creation of highly personalized treatment plans. These plans take into account the unique attributes of each patient's cancer, allowing oncologists to choose the most effective therapies. This increased treatment efficacy results in better patient outcomes and increased demand for AI-based oncology solutions. Personalized treatment plans not only focus on maximizing the effectiveness of treatment but also aim to minimize side effects. AI can predict how an individual patient will respond to specific treatments, helping to avoid therapies that are likely to cause severe adverse effects. Patients appreciate personalized plans that consider their well-being, leading to higher patient satisfaction and adherence to treatment. AI assists in identifying targeted therapies and immunotherapies that are most likely to be effective for a particular patient's cancer.

This reduces the trial-and-error approach in treatment selection and minimizes the use of ineffective drugs, resulting in cost savings for healthcare systems. AI algorithms can process complex datasets rapidly, providing oncologists with treatment recommendations in a shorter time frame. This acceleration in decision-making is particularly crucial in oncology, where timely treatment adjustments can significantly impact a patient's prognosis. Personalized treatment plans often require the participation of patients in clinical trials for experimental therapies. AI assists in identifying suitable candidates for these trials based on their genetic profiles and medical history. This facilitates the recruitment of appropriate participants, expedites the trials, and leads to quicker development and approval of innovative cancer treatments. In an era where patients are increasingly informed and involved in their healthcare decisions, personalized treatment plans align with the principles of patient-centered care. AI empowers patients by providing them with treatment options tailored to their unique circumstances, fostering a sense of control and engagement in their care.

Increasing Drug Discovery and Development

AI can analyze vast datasets, including genetic information and molecular data, to identify potential drug candidates more quickly and accurately than traditional methods. This acceleration in the drug discovery process reduces time and resources required for research and development, making it an attractive prospect for pharmaceutical companies looking to bring new cancer therapies to market. AI can help identify new and promising molecular targets for cancer treatment by analyzing large-scale genomic and proteomic data. This leads to the discovery of previously unexplored therapeutic avenues, increasing the potential for breakthrough treatments. AI models can predict the efficacy and safety of drug candidates in silico, reducing the need for expensive and time-consuming preclinical and clinical trials.

This saves pharmaceutical companies significant costs and expedites the drug development timeline. AI analyzes patient data to identify specific genetic mutations or biomarkers associated with a patient's cancer. This information can be used to develop personalized treatment options, including targeted therapies and precision medicine approaches. The ability to tailor treatments to individual patients drives the demand for AI solutions. AI can identify existing drugs with potential for repurposing in cancer treatment. By analyzing data on drug interactions and pathways, AI can suggest new applications for drugs already approved for other conditions, potentially speeding up the availability of cancer treatments. AI seamlessly integrates diverse sources of data, including clinical trials data, scientific literature, and real-world patient data. This holistic approach enables researchers to make data-driven decisions and gain comprehensive insights into drug development processes.


Download Free Sample Report

Key Market Challenges

Interoperability and Data Integration

Healthcare systems often use different electronic health record (EHR) systems, imaging platforms, and data formats. This fragmentation results in siloed data, making it difficult to access and integrate patient information from multiple sources. AI in oncology requires a comprehensive view of a patient's medical history, which is hindered by data fragmentation. Diverse systems may use different data standards and formats, making it challenging to ensure that AI algorithms can effectively process and analyze the data. Compatibility issues can lead to data loss, misinterpretation, or errors in AI-driven insights. Variations in data quality and completeness across different healthcare systems can affect the accuracy and reliability of AI models. Inconsistent data can lead to biased or incorrect recommendations, diminishing the trust in AI systems among healthcare professionals.

The process of integrating AI solutions with existing healthcare IT infrastructure can be expensive and time-consuming. Healthcare institutions may need to invest in custom solutions, middleware, or third-party services to ensure seamless data integration. Implementing data integration solutions can disrupt clinical workflows. Healthcare providers may resist changes that interfere with their established routines, potentially delaying or hindering the adoption of AI technologies. Healthcare data ownership and privacy regulations can vary by region, and navigating these complexities when sharing or integrating patient data can be challenging. Ensuring compliance with data protection laws while facilitating data sharing is a delicate balance.

Clinical Validation and Adoption

One of the primary barriers to the adoption of AI in oncology is the need for robust clinical evidence demonstrating the efficacy and safety of AI-driven tools. Healthcare providers and regulatory authorities often require substantial clinical validation before integrating AI solutions into clinical practice. The time and resources required for conducting extensive clinical trials can slow down the adoption of AI technologies. The healthcare industry is heavily regulated, and bringing AI-based oncology solutions to market requires navigating complex regulatory pathways. Meeting regulatory requirements, obtaining approvals, and ensuring compliance with evolving standards can be a challenging and time-consuming process.

Healthcare professionals, including oncologists, radiologists, and pathologists, may be hesitant to fully trust and adopt AI-driven recommendations. Skepticism, resistance to change, and concerns about the impact on their roles can impede the integration of AI tools into clinical workflows. AI algorithms often need to be validated across diverse patient populations to ensure their effectiveness across different demographic groups and cancer types. This can be a resource-intensive process and may require access to a wide range of patient data. Integrating AI solutions into existing healthcare IT systems can be complex. Ensuring compatibility with electronic health records (EHRs), radiology information systems, and laboratory information systems requires technical expertise and resources. The handling of patient data in AI systems raises concerns about data privacy and security. Ensuring that patient information remains confidential and is protected from cybersecurity threats is paramount but challenging.

Key Market Trends

AI-Driven Radiomics

AI-driven radiomics enhances the precision of cancer diagnosis. By analyzing subtle and complex patterns within medical images, AI can detect tumors and other abnormalities at earlier and often more treatable stages. This capability improves diagnostic accuracy and reduces the likelihood of missed or misinterpreted findings. Radiomics allows for the characterization of tumors at a granular level. AI can identify specific features within an image that correspond to the tumor's genetic and biological properties. This information is invaluable in developing personalized treatment plans tailored to the patient's unique cancer profile. Radiomics-based AI tools can monitor a patient's response to treatment over time.

By analyzing changes in imaging features, AI can help clinicians determine whether a treatment is effective or needs adjustment, enabling timely interventions and minimizing unnecessary side effects. AI-driven radiomics can aid in the early detection of cancer, even before clinical symptoms manifest. This is particularly crucial for cancers with aggressive progression rates. As AI algorithms become more proficient at identifying subtle image patterns, they will play a pivotal role in cancer screening programs. Human interpretation of medical images can be subjective and influenced by the interpreting radiologist's experience. AI-driven radiomics offers consistency and objectivity in image analysis, reducing interobserver variability and ensuring a higher standard of care across healthcare providers.

Genomic Sequencing and Precision Medicine

Genomic sequencing provides a detailed understanding of a patient's genetic makeup and identifies specific mutations or alterations driving their cancer. AI algorithms can analyze this genomic data to develop personalized treatment plans tailored to the patient's unique genetic profile. The ability to deliver targeted therapies significantly enhances treatment effectiveness, reducing side effects and improving patient outcomes. Genomic sequencing, coupled with AI, accelerates the identification of potential drug targets within a patient's tumor. AI analyzes the vast amount of genomic data generated in sequencing to pinpoint genes or pathways that are critical for the cancer's growth. This information is invaluable for drug development and personalized treatment strategies. AI can predict a patient's likely response to specific therapies based on their genomic profile.

This information guides oncologists in selecting the most appropriate treatment options, avoiding treatments that are unlikely to be effective, and minimizing trial-and-error approaches. Predictive analytics increase the likelihood of successful treatment and enhance patient care. Genomic sequencing and AI streamline the design and execution of clinical trials. AI identifies eligible patients with specific genomic markers, improving patient recruitment and reducing trial duration. This results in faster drug development and a more efficient clinical trial process. AI-driven precision medicine solutions provide oncologists with real-time decision support. When faced with complex treatment decisions, clinicians can rely on AI algorithms to analyze genomic data and recommend the most suitable treatment options, enhancing clinical decision-making and confidence.

Segmental Insights

Component Insights

Based on the Component, the software solutions segment is anticipated to witness substantial market growth throughout the forecast period. Improved AI-powered software solutions enhance the accuracy of cancer diagnosis by analyzing medical images, pathology slides, and genomic data. These tools can identify subtle patterns and anomalies that might be missed by human observers, leading to earlier and more precise diagnoses.Software solutions assist oncologists in developing personalized treatment plans based on patients' medical records, genomic data, and real-time clinical insights. These plans are tailored to the individual patient's cancer type, stage, and genetic profile, optimizing treatment outcomes. AI software solutions streamline the management and analysis of vast amounts of patient data, including electronic health records (EHRs), medical images, and genomic sequences. This efficiency reduces administrative burdens, accelerates data-driven decision-making, and enhances overall healthcare productivity.

AI software excels in radiomics, extracting quantitative features from medical images and pathology slides. These features offer valuable insights into tumor characteristics, treatment response, and prognosis. Radiomics-based software assists in identifying biomarkers and optimizing treatment approaches. Software solutions provide real-time clinical decision support to healthcare professionals. They offer recommendations for treatment options, dosages, and follow-up protocols, aiding clinicians in making well-informed decisions and ensuring standardized care practices.

Cancer Type Insights

Based on the Cancer Type segment, the breast cancer segment has been the dominant force in the market. AI algorithms can analyze mammograms and other breast imaging studies with high accuracy. By identifying subtle abnormalities and patterns, AI assists radiologists in early breast cancer detection. The ability to catch breast cancer at an earlier, more treatable stage is a crucial factor in improving patient outcomes. AI-driven tools can assess a patient's risk of developing breast cancer based on various factors, including genetics, family history, and lifestyle. This risk assessment can guide personalized prevention strategies, such as lifestyle modifications, increased screening frequency, or prophylactic measures for high-risk individuals. AI helps oncologists tailor treatment plans for breast cancer patients based on individual factors, such as tumor subtype, genetic mutations, and treatment response predictions. Personalized treatment approaches optimize therapeutic outcomes while minimizing side effects. AI assists pathologists in analyzing breast tissue samples and identifying cancerous cells, subtypes, and biomarkers with high precision. These insights are essential for selecting targeted therapies and predicting treatment response. Radiomics-based AI solutions extract quantitative features from breast imaging studies, providing valuable information about tumor characteristics and behavior. This data informs treatment planning and helps identify novel biomarkers.


Download Free Sample Report

Regional Insights

North America, specifically the AI in Oncology Market, dominated the market in 2022, primarily due to North America, particularly the United States, is a global leader in technology and innovation. The region boasts a robust ecosystem of AI developers, healthcare technology companies, and research institutions dedicated to advancing AI applications in oncology. This culture of innovation fosters the rapid development and adoption of AI-driven solutions. North America has one of the highest healthcare expenditure rates globally. The region's willingness to invest in cutting-edge healthcare technologies, including AI, creates a favorable environment for the growth of the AI in Oncology Market. North American institutions conduct extensive research and development in the field of oncology. Collaborations between academic research centers, pharmaceutical companies, and technology firms drive the development of AI-powered tools for cancer diagnosis, treatment, and research. North America has a significant population affected by cancer, particularly in the United States and Canada. The high incidence of cancer cases provides a substantial patient base for AI-driven solutions, making it an attractive market for healthcare providers and technology developers. North America boasts a robust healthcare infrastructure with advanced diagnostic imaging facilities, electronic health record (EHR) systems, and data repositories. These resources support the integration and implementation of AI tools in clinical practice.

Recent Developments

  • Whiterabbit.ai and Arterys agreed in August 2022 to develop AI-powered technology to identify cancer in its early stages.
  • Roche announced a collaboration with EarlySign in July 2022 to develop and commercialize their LungFlag technology.
  • Kheiron Medical Technologies formed a collaboration with Atlas Medical in 2021. The partnership aims to launch Mia, a breast cancer screening solution that more precisely assists radiologists in cancer detection.
  • Paige partnered with Quest Diagnostics in May 2021. The company hoped to deliver faster, more precise, and more brief clinical insights by developing new software.
  • Paige joined forces with Epredia in March 2021. Through this collaboration, the company aimed to help pathologists enable insights from each test and offer results to patients.
  • PathAI acquired Poplar in July 2021. The firm would be able to incorporate testing services into its emerging AI-powered pathology platform as a result of this acquisition.
  • In September 2021, Owkin, Inc., in collaboration with Cleveland Clinic researchers, announced the development of a deep-learning model that predicts survival and health outcomes for hepatocellular carcinoma.
  • In August 2022, Medtronic plc launched a GI GeniusTM intelligent endoscopy module in India. It is powered by AI and assists healthcare practitioners in the detection of colorectal cancer through enhanced visualization during colonoscopy.

Key Market Players

  • Azra AI.
  • IBM
  • Siemens Healthcare GmbH.
  • Intel Corporation.
  • GE HealthCare.
  • NVIDIA Corporation.
  • Digital Diagnostics Inc.
  • ConcertAI.
  • Median Technologies.
  • PathAI.

 By Component

By Cancer Type

By Treatment Type

By Region
  • Software Solutions
  • Hardware
  • Services
  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Brain Tumor
  • Others
  • Chemotherapy
  • Radiotherapy
  • Immunotherapy
  • Others
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

 

Report Scope:

In this report, the Global AI in Oncology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • AI in Oncology Market, By Component:

o   Software Solutions

o   Hardware

o   Services

  • AI in Oncology Market, By Cancer Type:

o   Breast Cancer

o   Lung Cancer

o   Prostate Cancer

o   Colorectal Cancer

o   Brain Tumor

o   Others

  • AI in Oncology Market, By Treatment Type:

o   Chemotherapy

o   Radiotherapy

o   Immunotherapy

o   Others

  • AI in Oncology Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

§  Kuwait

§  Turkey

§  Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global AI in Oncology Market.

Available Customizations:

Global AI in Oncology market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global AI in Oncology Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.    Markets Covered

1.2.2.    Years Considered for Study

1.2.3.    Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global AI in Oncology Market Outlook

5.1.  Market Size & Forecast

5.1.1.    By Value

5.2.  Market Share & Forecast

5.2.1.    By Component (Software Solutions, Hardware, Services)

5.2.2.    By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)

5.2.3.    By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)

5.2.4.    By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)

5.2.5.    By Company (2022)

5.3.  Market Map

5.3.1 By Component

5.3.2 By Cancer Type

5.3.3 By Treatment Type

5.3.4 By Region

6.    North America AI in Oncology Market Outlook

6.1.  Market Size & Forecast         

6.1.1.    By Value

6.2.  Market Share & Forecast

6.2.1.    By Component (Software Solutions, Hardware, Services)

6.2.2.    By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)

6.2.3.    By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)

6.2.4.    By Country

6.3.  North America: Country Analysis

6.3.1.    United States AI In Oncology Market Outlook

6.3.1.1.             Market Size & Forecast

6.3.1.1.1.            By Value

6.3.1.2.             Market Share & Forecast

6.3.1.2.1.            By Component

6.3.1.2.2.            By Cancer Type

6.3.1.2.3.            By Treatment Type

6.3.2.    Canada AI In Oncology Market Outlook

6.3.2.1.             Market Size & Forecast

6.3.2.1.1.            By Value

6.3.2.2.             Market Share & Forecast

6.3.2.2.1.            By Component

6.3.2.2.2.            By Cancer Type

6.3.2.2.3.            By Treatment Type

6.3.3.    Mexico AI In Oncology Market Outlook

6.3.3.1.             Market Size & Forecast

6.3.3.1.1.            By Value

6.3.3.2.             Market Share & Forecast

6.3.3.2.1.            By Component

6.3.3.2.2.            By Cancer Type

6.3.3.2.3.            By Treatment Type

7.    Europe AI In Oncology Market Outlook

7.1.  Market Size & Forecast         

7.1.1.    By Value

7.2.  Market Share & Forecast

7.2.1.    By Component (Software Solutions, Hardware, Services)

7.2.2.    By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)

7.2.3.    By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)

7.2.4.    By Country

7.3.  Europe: Country Analysis

7.3.1.    France AI In Oncology Market Outlook

7.3.1.1.             Market Size & Forecast

7.3.1.1.1.            By Value

7.3.1.2.             Market Share & Forecast

7.3.1.2.1.            By Component

7.3.1.2.2.            By Cancer Type

7.3.1.2.3.            By Treatment Type

7.3.2.    Germany AI In Oncology Market Outlook

7.3.2.1.             Market Size & Forecast

7.3.2.1.1.            By Value

7.3.2.2.             Market Share & Forecast

7.3.2.2.1.            By Component

7.3.2.2.2.            By Cancer Type

7.3.2.2.3.            By Treatment Type

7.3.3.    United Kingdom AI In Oncology Market Outlook

7.3.3.1.             Market Size & Forecast

7.3.3.1.1.            By Value

7.3.3.2.             Market Share & Forecast

7.3.3.2.1.            By Component

7.3.3.2.2.            By Cancer Type

7.3.3.2.3.            By Treatment Type

7.3.4.    Italy AI In Oncology Market Outlook

7.3.4.1.             Market Size & Forecast

7.3.4.1.1.            By Value

7.3.4.2.             Market Share & Forecast

7.3.4.2.1.            By Component

7.3.4.2.2.            By Cancer Type

7.3.4.2.3.            By Treatment Type

7.3.5.    Spain AI In Oncology Market Outlook

7.3.5.1.             Market Size & Forecast

7.3.5.1.1.            By Value

7.3.5.2.             Market Share & Forecast

7.3.5.2.1.            By Component

7.3.5.2.2.            By Cancer Type

7.3.5.2.3.            By Treatment Type

8.    Asia-Pacific AI In Oncology Market Outlook

8.1.  Market Size & Forecast         

8.1.1.    By Value

8.2.  Market Share & Forecast

8.2.1.    By Component (Software Solutions, Hardware, Services)

8.2.2.    By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)

8.2.3.    By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)

8.2.4.    By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.    China AI In Oncology Market Outlook

8.3.1.1.             Market Size & Forecast

8.3.1.1.1.            By Value

8.3.1.2.             Market Share & Forecast

8.3.1.2.1.            By Component

8.3.1.2.2.            By Cancer Type

8.3.1.2.3.            By Treatment Type

8.3.2.    India AI In Oncology Market Outlook

8.3.2.1.             Market Size & Forecast

8.3.2.1.1.            By Value

8.3.2.2.             Market Share & Forecast

8.3.2.2.1.            By Component

8.3.2.2.2.            By Cancer Type

8.3.2.2.3.            By Treatment Type

8.3.3.    Japan AI In Oncology Market Outlook

8.3.3.1.             Market Size & Forecast

8.3.3.1.1.            By Value

8.3.3.2.             Market Share & Forecast

8.3.3.2.1.            By Component

8.3.3.2.2.            By Cancer Type

8.3.3.2.3.            By Treatment Type

8.3.4.    South Korea AI In Oncology Market Outlook

8.3.4.1.             Market Size & Forecast

8.3.4.1.1.            By Value

8.3.4.2.             Market Share & Forecast

8.3.4.2.1.            By Component

8.3.4.2.2.            By Cancer Type

8.3.4.2.3.            By Treatment Type

8.3.5.    Australia AI In Oncology Market Outlook

8.3.5.1.             Market Size & Forecast

8.3.5.1.1.            By Value

8.3.5.2.             Market Share & Forecast

8.3.5.2.1.            By Component

8.3.5.2.2.            By Cancer Type

8.3.5.2.3.            By Treatment Type

9.    South America AI In Oncology Market Outlook

9.1.  Market Size & Forecast         

9.1.1.    By Value

9.2.  Market Share & Forecast

9.2.1.    By Component (Software Solutions, Hardware, Services)

9.2.2.    By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)

9.2.3.    By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)

9.2.4.    By Country

9.3.  South America: Country Analysis

9.3.1.    Brazil AI In Oncology Market Outlook

9.3.1.1.             Market Size & Forecast

9.3.1.1.1.            By Value

9.3.1.2.             Market Share & Forecast

9.3.1.2.1.            By Component

9.3.1.2.2.            By Cancer Type

9.3.1.2.3.            By Treatment Type

9.3.2.    Argentina AI In Oncology Market Outlook

9.3.2.1.             Market Size & Forecast

9.3.2.1.1.            By Value

9.3.2.2.             Market Share & Forecast

9.3.2.2.1.            By Component

9.3.2.2.2.            By Cancer Type

9.3.2.2.3.            By Treatment Type

9.3.3.    Colombia AI In Oncology Market Outlook

9.3.3.1.             Market Size & Forecast

9.3.3.1.1.            By Value

9.3.3.2.             Market Share & Forecast

9.3.3.2.1.            By Component

9.3.3.2.2.            By Cancer Type

9.3.3.2.3.            By Treatment Type

10.  Middle East and Africa AI In Oncology Market Outlook

10.1.               Market Size & Forecast         

10.1.1.  By Value

10.2.               Market Share & Forecast

10.2.1.  By Component (Software Solutions, Hardware, Services)

10.2.2.  By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)

10.2.3.  By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)

10.2.4.  By Country

10.3.               MEA: Country Analysis

10.3.1.  South Africa AI In Oncology Market Outlook

10.3.1.1.          Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.          Market Share & Forecast

10.3.1.2.1.         By Component

10.3.1.2.2.         By Cancer Type

10.3.1.2.3.         By Treatment Type

10.3.2.  Saudi Arabia AI In Oncology Market Outlook

10.3.2.1.          Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.          Market Share & Forecast

10.3.2.2.1.         By Component

10.3.2.2.2.         By Cancer Type

10.3.2.2.3.         By Treatment Type

10.3.3.  UAE AI In Oncology Market Outlook

10.3.3.1.          Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.          Market Share & Forecast

10.3.3.2.1.         By Component

10.3.3.2.2.         By Cancer Type

10.3.3.2.3.         By Treatment Type

11.  Market Dynamics

11.1.               Drivers

11.2.               Challenges

12.  Market Trends & Developments

12.1.               Recent Development

12.2.               Mergers & Acquisitions

12.3.               Product Launches

13.  Global AI In Oncology Market: SWOT Analysis

14.  Porter’s Five Forces Analysis

14.1.               Competition in the Industry

14.2.               Potential of New Entrants

14.3.               Power of Suppliers

14.4.               Power of Customers

14.5.               Threat of Substitute Products

15.  Competitive Landscape

15.1.               Azra AI.

15.1.1.  Business Overview

15.1.2.  Product Offerings

15.1.3.  Recent Developments

15.1.4.  Financials (As Reported)

15.1.5.  Key Personnel

15.1.6.  SWOT Analysis

15.2.               IBM Corp.

15.3.               Siemens Healthcare GmbH.

15.4.               Intel Corporation.

15.5.               GE HealthCare.

15.6.               NVIDIA Corporation.

15.7.               Digital Diagnostics Inc.

15.8.               ConcertAI.

15.9.               Median Technologies.

15.10.            PathAI.

16.  Strategic Recommendations

17.  About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global AI in Oncology Market was estimated to be USD 701.08 Million in 2022.

down-arrow

The Chemotherapy segment demonstrated significant dominance in 2022, primarily due to incorporation of AI to provide tailored chemotherapy with reduced dosage and fewer side effects enhances the adoption of chemotherapy.

down-arrow

North America emerged as the dominant market in 2022, capturing a significant revenue share due to the presence of well-developed digital infrastructure, favorable regulatory and reimbursement policies, and rising government initiatives to boost the adoption of AI technology in the healthcare industry.

down-arrow

The advancement of technology and the use of AI in cancer diagnostics and The demand for technological advancements in the healthcare field for cancer detection and screening a lack of exercise will propel Global AI in Oncology market growth during the forecast period.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

AI in Oncology Market to Grow with a CAGR of 14.02% through 2028

Sep, 2023

Increasing awareness of the importance of early cancer detection is expected to drive the Global AI in Oncology Market growth in the forecast period, 2024-2028.

Why Choose Us